Balyasny Asset Management LLC cut its position in shares of Qiagen N.V. (NASDAQ:QGEN) by 60.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 656,736 shares of the company’s stock after selling 1,015,272 shares during the quarter. Balyasny Asset Management LLC owned 0.29% of Qiagen N.V. worth $22,020,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the stock. Acrospire Investment Management LLC boosted its position in Qiagen N.V. by 11.7% during the second quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock worth $112,000 after purchasing an additional 349 shares in the last quarter. FNY Managed Accounts LLC acquired a new stake in Qiagen N.V. in the first quarter valued at $103,000. Oppenheimer Asset Management Inc. acquired a new stake in Qiagen N.V. in the first quarter valued at $114,000. Quantitative Systematic Strategies LLC acquired a new stake in Qiagen N.V. in the second quarter valued at $211,000. Finally, Prudential Financial Inc. acquired a new stake in Qiagen N.V. in the first quarter valued at $207,000. 63.01% of the stock is owned by hedge funds and other institutional investors.

Qiagen N.V. (QGEN) opened at 31.80 on Monday. The firm has a 50-day moving average of $31.87 and a 200-day moving average of $31.77. Qiagen N.V. has a 12-month low of $24.89 and a 12-month high of $35.26. The stock has a market capitalization of $7.26 billion, a price-to-earnings ratio of 97.25 and a beta of 1.14.

Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The company had revenue of $349.00 million during the quarter, compared to the consensus estimate of $353.09 million. During the same quarter in the prior year, the firm earned $0.24 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Equities research analysts forecast that Qiagen N.V. will post $1.21 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/balyasny-asset-management-llc-trims-position-in-qiagen-n-v-qgen/1603013.html.

A number of brokerages have recently weighed in on QGEN. Zacks Investment Research cut Qiagen N.V. from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub upgraded shares of Qiagen N.V. from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Wells Fargo & Company reiterated a “market perform” rating and issued a $31.00 price objective (up from $28.00) on shares of Qiagen N.V. in a research report on Thursday, July 13th. Commerzbank Ag reissued a “buy” rating on shares of Qiagen N.V. in a research note on Tuesday, June 6th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $28.00 price objective (up from $25.00) on shares of Qiagen N.V. in a research note on Monday, July 31st. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Qiagen N.V. currently has an average rating of “Hold” and a consensus target price of $33.17.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).

Institutional Ownership by Quarter for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.